Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giovanni Selvaggi

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
Clinical Lung Cancer|December 5, 2003
Chemotherapy in advanced non-small-cell lung cancer: a look behind and aheadGiovanni Selvaggi, Giorgio V Seagliotti
Expert Opinion on Emerging Drugs|March 16, 2007
Emerging drugs for mesotheliomaGiorgio Vittorio Scagliotti, Giovanni Selvaggi
Clinical Lung Cancer|May 8, 2009
New data integrating multitargeted antifolates into treatment of first-line and relapsed non-small-cell lung cancerGiorgio Vittorio Scagliotti, Giovanni Selvaggi
Oncology (Williston Park, N.Y.)|January 2, 2010
Histologic subtype in NSCLC: does it matter?Giovanni Selvaggi, Giorgio V Scagliotti
Expert Opinion on Therapeutic Patents|February 11, 2010
Antimetabolites and cancer: emerging data with a focus on antifolatesGiorgio V Scagliotti, Giovanni Selvaggi
Critical Reviews in Oncology/Hematology|June 28, 2005
Management of bone metastases in cancer: a reviewGiovanni Selvaggi, Giorgio V Scagliotti
Expert Review of Respiratory Medicine|May 19, 2010
Perspectives in adjuvant chemotherapy in NSCLCGiovanni Selvaggi, Giorgio Vittorio Scagliotti
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2004
The biology of epidermal growth factor receptor in lung cancerGiorgio V Scagliotti, Giovanni Selvaggi, Silvia Novello, et al.
Investigational New Drugs|February 20, 2015
The oncolytic virus, pelareorep, as a novel anticancer agent: a reviewRomit Chakrabarty, Hue Tran, Giovanni Selvaggi, et al.
Frontiers in Oncology|April 25, 2022
Targeting ALK Rearrangements in NSCLC: Current State of the ArtLing Peng, Liping Zhu, Yilan Sun, et al.
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
Clinical Lung Cancer|December 5, 2003
Chemotherapy in advanced non-small-cell lung cancer: a look behind and aheadGiovanni Selvaggi, Giorgio V Seagliotti
Expert Opinion on Emerging Drugs|March 16, 2007
Emerging drugs for mesotheliomaGiorgio Vittorio Scagliotti, Giovanni Selvaggi
Clinical Lung Cancer|May 8, 2009
New data integrating multitargeted antifolates into treatment of first-line and relapsed non-small-cell lung cancerGiorgio Vittorio Scagliotti, Giovanni Selvaggi
Oncology (Williston Park, N.Y.)|January 2, 2010
Histologic subtype in NSCLC: does it matter?Giovanni Selvaggi, Giorgio V Scagliotti
Expert Opinion on Therapeutic Patents|February 11, 2010
Antimetabolites and cancer: emerging data with a focus on antifolatesGiorgio V Scagliotti, Giovanni Selvaggi
Critical Reviews in Oncology/Hematology|June 28, 2005
Management of bone metastases in cancer: a reviewGiovanni Selvaggi, Giorgio V Scagliotti
Expert Review of Respiratory Medicine|May 19, 2010
Perspectives in adjuvant chemotherapy in NSCLCGiovanni Selvaggi, Giorgio Vittorio Scagliotti
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2004
The biology of epidermal growth factor receptor in lung cancerGiorgio V Scagliotti, Giovanni Selvaggi, Silvia Novello, et al.
Investigational New Drugs|February 20, 2015
The oncolytic virus, pelareorep, as a novel anticancer agent: a reviewRomit Chakrabarty, Hue Tran, Giovanni Selvaggi, et al.
Frontiers in Oncology|April 25, 2022
Targeting ALK Rearrangements in NSCLC: Current State of the ArtLing Peng, Liping Zhu, Yilan Sun, et al.
Pageof 4